International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy (STOP-HCC)
Surveillance and Treatment Of Primary Hepatocellular Carcinoma: An International Cohort Study of High-Risk Patients for HCC Using Liquid Biopsy
Sponsor: Johns Hopkins University
Terminated
PI moving on from current institution
A observational or N/A phase clinical study on Early Stage Liver Cancer and Hepatocellular Carcinoma, this trial is terminated or withdrawn. The trial is conducted by Johns Hopkins University and has accumulated 10 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Terminated
-
Jul 2025 — Sep 2025 [monthly]
Terminated
Status: Recruiting → Terminated
-
Mar 2025 — Jul 2025 [monthly]
Recruiting
-
Feb 2025 — Mar 2025 [monthly]
Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Recruiting
▶ Show 5 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Feb 2024 — Jul 2024 [monthly]
Recruiting
Status: Active Not Recruiting → Recruiting
-
Jun 2023 — Feb 2024 [monthly]
Active Not Recruiting
-
Jun 2022 — Jun 2023 [monthly]
Active Not Recruiting
-
May 2022 — Jun 2022 [monthly]
Active Not Recruiting
First recorded
Apr 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Johns Hopkins University
- King Faisal Specialist Hospital & Research Center
- Medic Medical Center (Viet Nam)
For direct contact, visit the study record on ClinicalTrials.gov .